Figure 3.

Pharmacologic inhibition of PDGFRA. (A) Dose response of imatinib and crenolanib treatment on SUM149 and KPL-4 cells grown in monolayer. Cells were treated with a dose range from 0 to 200 μM imatinib or 0 to 20 μM crenolanib for 48 hours and assessed by MTT. Effect on cell survival was compared in parallel with vehicle controls. Error bars represent SD, *P ≤ .001. ND = not done. (B) Cell cycle analysis by propidium iodide staining of SUM149 cells treated with 2 μM or 5 μM crenolanib for 12 hours. Untreated and DMSO-treated cells were used as controls. FACS analysis data were processed using CellQuest and Mod-Fit software. The bar graph is quantification of the data showing the percentage of cells in G₁, G₂/M, and S phases, Error bars represent SD,*P ≤ .05. (C) Dose response of imatinib and crenolanib treatment on SUM149 and KPL-4 cells grown as three-dimensional emboli. Cells were treated with a dose range from 0 to 200 μM imatinib or 0 to 5 μM crenolanib for 48 hours; emboli were harvested and assessed by direct counting, which was compared in parallel with vehicle controls. Error bars represent SD, *P ≤ .001. Each experiment was performed in at least triplicate.